Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)
Status:
Completed
Trial end date:
2010-08-20
Target enrollment:
Participant gender:
Summary
This is a randomized, active-controlled, parallel-group, single-dose, multi-site,
safety-assessor blinded study comparing sugammadex to neostigmine for reversal of
neuromuscular blockade in Korean subjects undergoing elective surgical procedures under
general anesthesia that require rocuronium for neuromuscular blockade. Study medication will
be administered at reappearance of T2. Time to recovery will be measured from start of study
medication administration to recovery of the T4/T1 ratio of 0.9. The primary hypothesis is
that the time to recovery of the T4/T1 ratio of 0.9 is shorter with sugammadex than with
neostigmine.